Dept. of Medical Informatics and Clinical Epidemiology
Oregon Health & Science University
Premature infants are at risk of developing significant anemia with adverse clinical outcome, yet blood transfusions used to treat anemia carry additional risks. Studies have investigated the use of recombinant erythropoietin (r-Epo) to reduce the need for blood transfusions. The beneficial impact of r-Epo use is controversial, and the original studies and meta-analyses were hampered by significant heterogeneity across trials, particularly in gestational age/birth weight, r-Epo dose, and transfusion criteria, as well as variation in the quality of evidence. Medical decision analytic models offer an advantage given the ability to combine evidence from multiple sources, and to focus the analysis on the outcomes of specific interest to the decision maker. However, standard approaches to address uncertainty in medical decision modeling seldom account for the uncertainty related to the quality of the evidence. A medical decision model was created to evaluate the cost-effectiveness of eithe
School of Medicine
Merrill, Jeffrey D., "Incorporation of uncertainty into a medical decision model of erthropoietin use in premature infants at risk for red cell transfusion" (2011). Scholar Archive. 659.